This story was originally published May 20
GATC Biotech said last week that is has won a €750,000 ($930,000) contract from a German research consortium to sequence pediatric brain tumors for a project that is part of the International Cancer Genome Consortium.
Under the contract, the German sequencing service provider will use Illumina sequencing technology, including a HiSeq 2000 instrument the company received this week, to sequence the genomes of brain tumors and matching normal controls from the same patient at 30-fold coverage. It expects to provide the data to the German Cancer Research Center, DKFZ, which manages the project, this fall.
Last year, the PedBrain Tumor Consortium, which includes researchers from seven institutions in Germany, won €15 million ($18.6 million) in funding over five years from the German Federal Ministry for Education and Research and German Cancer Aid, a charity, to study the genomics of two childhood brain cancers, medulloblastoma and pylocytic astrocytoma (IS 12/15/2009).
Under the project, which is part of the ICGC, the researchers plan to comprehensively analyze 300 tumor samples and matched controls, with the goal to discover new therapeutic targets, diagnostic biomarkers, and predictors of treatment response.